YES = formulary NO = non-formulary NO BENEFIT = excluded
|
|
- Martha Gordon
- 5 years ago
- Views:
Transcription
1 Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular group of generic equivalent medicines which is reviewed and updated regularly. MRP sets a maximum reimbursable price for a list of generically similar medicines with a cost lower than that of the original medicine. There may be instances where a generic alternative costs more than the set MRP. If you opt to use the original medicine and a generic alternative is available, or you use a medicine that costs more than the MRP, you will have to pay the difference between the price of the chosen medicine and that of MRP. This formulary is effective from 1 January This formulary is subject to change without notice. ONLY the following medicine classes will be considered for Beat1 and Beat2: Anticholinergic Methylxanthine Oral corticosteroids Penicillin Sympathomimetics Tetracyclines BRONCHIECTASIS YES = formulary = non-formulary = excluded ACTIVE INGREDIENT A AMOXYCILLIN ADCO-AMOX 125MG SUSP ADCO-AMOX 250MG CAP YES ADCO-AMOX 250MG SUSP ADCO-AMOX 500MG CAP YES A-LENN AMOXYCILLIN 125 YES A-LENN AMOXYCILLIN 250M YES ALLMOX 250MG CAP YES ALLMOX 500MG CAP YES AMOCAS 250MG CAP YES AMOCILLIN 250MG CAP YES AMOCILLIN 125MG SUSP AMOCILLIN 500MG CAP YES AMOXICAP 250MG CAP YES AMOXICILLIN HEXAL 500MG YES AMOXIL 250MG CAP YES 1
2 AMOXIL 500MG CAP YES AMOXIL S 125MG SUSP AMOXIL SF 250MG SUSP AURO-AMOXYCILLIN 250MG CAP YES AURO-AMOXYCILLIN 500MG CAP YES AUSTELL-AMOXICILLIN 250MG YES AUSTELL-AMOXICILLIN 500MG YES BETAMOX 250MG CAP YES BETAMOX 500MG CAP YES BETAMOX S 125MG/5ML SUS BETAMOX SF 250MG/5ML SUS DYNA-AMOXYCIL 125MG/5ML IPCAMOX 250MG CAP YES MOXYMAX 125 SUSP MOXYMAX 250 SUSP MOXYPEN 125 SUSP MOXYPEN 250MG CAP YES MOXYPEN 250MG/5ML SUSP MOXYPEN 500MG CAP YES MYMOX 250MG CAP YES MYMOX 500MG CAP YES PROMOXIL 250MG CAP YES PROMOXIL 500MG CAP YES PROMOXIL S 125MG/5ML PROMOXIL SF 250MG/5ML RANMOXY 250MG CAP YES RANMOXY 500MG CAP YES RANMOXY SUSP 125MG RANMOXY SUSP 250MG SALTERMOX S 125MG/5ML SALTERMOX SF 250MG/5ML ZALOXY 125MG/5ML SUSP ZALOXY 250MG CAP YES 2
3 ZALOXY 250MG/5M SUSP ZALOXY 500MG CAP YES ZOXIL 250MG CAP YES ZOXIL 500MG CAP YES ZOXIL S 125MG/5ML SUS ZOXIL SF 250MG/5ML SUS AMOXICILLIN / CLAVULANIC ADCO-AMOCLAV 375 ADCO-AMOCLAV 625 ADCO-AMOCLAV BD 1000MG ADCO-AMOCLAV S ADCO-AMOCLAV SF AMOCLAN TAB AMOCLAN BID 1000MG TAB AMOCLAN FORTE TAB AMOCLAN S SUSP AMOCLAN SF SUSP APEX-CLAVUTIN 375MG TAB APEX-CLAVUTIN 625MG TAB APEX-CLAVUTIN SF AUGMAXCIL 375 AUGMAXCIL 625 AUGMAXCIL S AUGMAXCIL SF AUGMENTIN 375MG TAB AUGMENTIN 625MG TAB AUGMENTIN 1000MG BD TAB AUGMENTIN BD S SUSP AUGMENTIN BD SF SUSP AUGMENTIN S SUSP AUGMENTIN SF SUSP AUGMENTIN SR 1000MG AURO-AMOXICLAV 1000MG TAB AURO-AMOXICLAV 125/31.25MG 3
4 AURO-AMOXICLAV 250/62.5 MG AURO-AMOXICLAV 375MG TAB AURO-AMOXICLAV 625MG TAB AUSTELL-CO-AMOXICLAV 375MG AUSTELL-CO-AMOXICLAV 625MG BIO-AMOKSIKLAV 1000MG TAB BIO-AMOKSIKLAV 156 SUSP BIO-AMOKSIKLAV 312 SUSP BIO-AMOKSIKLAV 375 BIO-AMOKSIKLAV 625 TAB CLAMENTIN 1000MG TAB CLAMENTIN 375MG CLAMENTIN S CLAMENTIN SF CLAVUMOX 375MG CLAVUMOX S CLAVUMOX SF CURAM 1000GM BD TAB CURAM 625MG TAB CURAM BD SUSP FORCID SOLUTAB 875/125 MOXYCLAV 375MG MOXYCLAV S MOXYCLAV SF RANCLAV 1000MG TAB RANCLAV 375MG RANCLAV 625MG RANCLAV FORTE SUSPENSION RANCLAV SUSPENSION SANDOZ CO AMOCLAV S SANDOZ CO AMOCLAV SF SANDOZ CO AMOXYCLAV 375 SANDOZ CO-AMOXYCLAV BD 1 4
5 SANDOZ CO-AMOXYCLAV 625 SANDOZ CO-AMOXYCLAV BD AMPICILLIN AMPIPEN 250MG CAP BE-AMPICIL 125MG SUSP BE-AMPICIL 250MG CAP SANDOZ AMPICILLIN 250MG B BECLOMETHASONE BECLATE 50MCG INHALER BECLATE 100MCG INHALER BECLATE 200MCG INHALER BECEZE 50MCG INHALER BECEZE 100MCG INHALER BECOTIDE DISKHALER YES BECOTIDE ROTACAPS 100 YES BECOTIDE ROTACAPS 200 YES BECOTIDE ROTAHALER YES QVAR AUTOHALER 100MCG YES QVAR AUTOHALER 50MCG YES QVAR PRESS/BREATH 100MCG YES QVAR PRESS/BREATH 50MCG YES BETAMETHASONE BETAID 0.6MG/5ML SYR STEROMIEN 0.6MG/5ML SYR BUDESONIDE BUDEFLAM DP 200MCG INH CA 5
6 BUDEFLAM HFA 100MCG 300D BUDEFLAM HFA 200MCG 300D INFLAMMIDE 100MCG INH 300 INFLAMMIDE 200 MCG VOLI INFLAMMIDE 200MCG INH 300 INFLAMMIDE 400MCG VOLI INFLAMMIDE 50MCG INH 300D INFLAMMIDE COMP VOLIZER INFLAMMIDE REF VOLIZER PULMICORT TURBU 100MCG YES PULMICORT TURBU 200MCG YES PULMICORT TURBU 400MCG YES BUDESONIDE / FORMOTEROL SYMBICORD INH 320/9MCG YES SYMBICORD INH 80/4.5MCG YES SYMBICORD TURBU 160/4.5 YES SYMBICORD TURBU 160/ YES VANNAIR 160/4.5MCG INH YES VANNAIR 80/4.5MCG INH YES D DOXYCYLINE A-LENN DOXYCYCLINE HCL YES CYCLIDOX 100MG CAP YES 6
7 CYCLIDOX EC 100MG CAP YES CYCLIDOX EC 50MG CAP YES DOXITAB YES DOXYCYL 50MG CAP YES DOXYCYL 100MG CAP YES DUMOXIN 50MG CAP YES I IPRATROPIUM ATROVENT 20 HFA 200DOSE YES IPVENT-40MCG INH 300DOSE YES IPVENT 40 HFA INH YES IPRATROPIUM / SALBUTAMOL COMBIVENT INHALER YES DUOLIN HFA 200DOSE INH YES F FETEROL BEROTEC 100 HFA 200DOSE YES FETEROL / IPRATROPIUM DUOVENT HFA 200DOSE INH FLUTICASONE FLIXOTIDE 125 CFC FREE YES FLIXOTIDE 250 CFC FREE YES FLIXOTIDE 50MCG CFC FREE YES FLIXOTIDE ACUHALER 50MCG YES FLIXOTIDE ACUHALER 100MCG YES FLIXOTIDE ACUHALER 250MCG YES FLIXOTIDE ACUHALER 500MCG YES FORMOTEROL FORADIL INHALETS FORATEC DP INH CAP FORATEC HFA 120 DOSE INH OXIS TURBUHALER YES P PHEXYMETHYLPENICILLIN BETAPEN 125MG/5ML SYR BETAPEN 250MG TAB 7
8 PREDNISONE BE-TABS PREDNISONE 5MG TAB YES METICORTEN 5MG TAB YES PANAFCORT 5MG TAB YES TROLIC 5MG TAB YES S SALBUTAMOL ASTHAVENT 200D ECOHALER YES ASTHAVENT 300D ECOHALER YES ASTHAVENT DP 200MCG CAP ASTHAVENT INH 200D YES VENTEZE CFC FREE 200 DOSE YES VENTEZE INH COMP 200D YES VENTIMAX CFC FREE 100MCG YES VENTOLIN INH 200D CFC-FRE YES SALMETEROL SEREVENT ACCUHALER YES SEREVENT CFC-FREE 120DOSE YES SEREVENT INHALER 120 YES SALMETEROL / FLUTICASONE FOXAIR 25/ DOSE YES FOXAIR 25/ DOSE YES FOXAIR 25/ DOSE YES FOXAIR 50/100 ACCUHALER YES FOXAIR 50/250 ACCUHALER YES FOXAIR 50/500 ACCUHALER YES SEREFLO 25/125 YES SEREFLO 25/250 YES SEREFLO 25/50 YES SERETIDE 25/ DOSE YES 8
9 SERETIDE 25/ DOSE YES SERETIDE 25/ DOSE YES SERETIDE 50/100 ACCUHALER YES SERETIDE 50/250 ACCUHALER YES SERETIDE 50/500 ACCUHALER YES T THEOPHYLLINE EUPHYLLIN RET 250MG YES RSTAN-TED 200MG TAB YES NUELIN SA 250 YES SANDOZ THEOPHYLLINE 200 YES SANDOZ THEOPHYLLINE 300 YES THEOPLUS 200MG TAB YES THEOPLUS 300MG TAB YES DEVICES DP HALER DEVICE REVOLIZER UNI VACCINES FLUARIX PREFILLED SYRINGE YES FLUVAX 2009 PRE-FILLED YES IMOVAX PNEUMO 23 YES INFLUVAC 0.5ML YES MUTAGRIP SINGLE DOSE YES PNEUMOVAX VAC YES VAXIGRIP PREFIL S/DOSE YES X-FLU PREFILLED SYR 0.5ML YES 9
YES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 B BECLOMETHASONE BECEZE 50MCG INHALER
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
More informationCYSTIC FIBROSIS. Pace4 Pace3 Pace2 A AMOXYCILLIN ADCO-AMOX 125MG SUSP YES ADCO-AMOX 500MG CAP ADCO-AMOX 250MG SUSP A-LENNON AMOXYCILLIN 250M
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
More informationCopyright Mediscor PBM (Pty) Ltd. This document is the property of Mediscor PBM (Pty) Ltd. Unauthorised use and distribution is prohibited.
Publication Date : 2014-07-30 Page 1 700315001 IBUCINE SUSP IBUPROFEN SUSP 100 MG/5ML ANALGESIC AND ANTIPYRETICS Y N Y 704781001 IBUGESIC 100MG/5ML SUSP IBUPROFEN SUSP 100 MG/5ML ANALGESIC AND ANTIPYRETICS
More informationCOMPREHENSIVE PMB FORMULARY 1-Dec-16
COMPREHENSIVE PMB FORMULARY 1-Dec-16 Depending on the specific scheme option, products included on this chronic medicines formulary will not attract a co-payment if authorised by Chronic Medicine Management
More informationInhalers containing CFCs. CFC-free inhalers
Propellants used in medical metered dose inhalers and aerosol-based breath activated devices in New Zealand August to October 2002 (most recent period for which data is available) (February 2003) Inhalers
More informationYES = formulary NO = non-formulary NO BENEFIT = excluded
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
More informationBONCAP Chronic Formulary 1-Jan-15
BONCAP Chronic Formulary 1-Jan-15 KEY to Chronic Medicine Management Reimbursement Criteria: Quantity/dosage and duration of authorisation may vary - depending on the requested drug. Accepted Treatment
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationACNE - SEVERE. Pace4 Pace3 Pace2 Pace1 Beat 4 Beat3. Pace4 Pace3 Pace2 Pace1 Beat 4 Beat3 MEDICINE NAME MEDICINE NAME
ACNE - SEVERE Pace Beat 4 Beat3 Pace Beat 4 Beat3 A ACNETANE 0 CYCLIDOX EC 00MG CAP ACNETANE 20 CYCLIMYCIN 00MG CAP ADCO-CO-TRIMOXAZOLE CYCLIMYCIN 50MG CAP ADCO-ERYTHROMYCIN 250 CAP CYPRENE-35 ED TAB ADCO-FEM
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationPOLMED COMPREHENSIVE PMB FORMULARY Aug-18
POLMED COMPREHENSIVE PMB FORMULARY Aug-18 Depending on the specific scheme option, products included on this chronic medication formulary will not attract a co-payment if authorised by Chronic Medicine
More informationYES = formulary NO = non-formulary NO BENEFIT = excluded
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
More informationYES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 A NO BENEFIT SANDOZ AMITRIPTYLINE 25
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
More informationFOR LONG TERM CORTICOSTEROIDS ONLY FOR SEVERE PERSISTENT ASTHMA (MOTIVATION REQUIRED FROM SPECIALIST)
NEDGROUP TRADITIONAL, COMPREHENSIVE AND PLATINUM PLANS A clinically relevant motivation is required when prescribing any product which does not appear on this list. Chronic application forms must accompany
More informationNEDGROUP HOSPITAL AND SAVINGS PLAN
NEDGROUP HOSPITAL AND SAVINGS PLAN A clinically relevant motivation is required when prescribing any product which does not appear on this list. Chronic application forms must accompany all first-time
More informationMinistry of Health. BC Chronic Disease and Selected Procedure Case Definitions. Chronic Disease Information Working Group. Date Created: June 29, 2015
Ministry of Health BC Chronic Disease and Selected Procedure Case Definitions Author: Chronic Disease Information Working Group Date Created: June 29, 2015 Last Updated: February 01, 2018 Version: Email:
More informationFor long term corticosteriod use. Only for severe persistent asthma (motivation required from specialist)
NEDGROUP TRADITIONAL, COMPREHENSIVE AND PLATINUM PLANS A clinically relevant motivation is when prescribing any product which does not appear on this list. Chronic application forms must accompany all
More informationFor long term corticosteriod use
NEDGROUP TRADITIONAL, COMPREHENSIVE AND PLATINUM PLANS A clinically relevant motivation is when prescribing any product which does not appear on this list. Chronic application forms must accompany all
More informationBONITAS STANDARD FORMULARY September 2018
BONITAS STANDARD FORMULARY September 2018 Reimbursement of all formulary items is subject to the Chronic Medicine Management clinical guidelines and protocols and the Medicine Price List (MPL). Nappi code
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
More information12:00 Autonomic Drugs 12:00. Autonomic Drugs
Autonomic Drugs Autonomic Drugs 12:04 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS PILOCARPINE HCL 5 MG ORAL TABLET 00002216345 SALAGEN 1.4298 PYRIDOSTIGMINE BROMIDE 60 MG ORAL TABLET 00000869961 MESTINON
More informationFirst to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction
More informationRestrictive Formulary. RESTRICTIVE PMB FORMULARY Effective 1 June 2010
RESTRICTIVE PMB FORMULARY Effective 1 June 2010 Products included on this chronic medicines formulary will not attract a co-payment if authorised by Chronic Medicine Management (Medi-Serve) for a disease
More informationProposal on subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers.
30 August 2011 Proposal on changes for some respiratory products and access restrictions to combination inhalers. As notified on 16 June 2011, PHARMAC has been considering options for managing the funding
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationPlease also see section on Drugs used in substance dependence for patients with established chemical dependence
Respiratory System Algorithm for the selection of the most appropriate inhaler device for patients with chronic stable asthma Information on Inhaler devices Devices β 2 agonist bronchodilators Antimuscarinic
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationYES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 A NO BENEFIT SANDOZ AMITRIPTYLINE 25
Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular
More informationacute medicine formulary 2013
medihelp necesse acute medicine formulary 2013 January 2013 version 1.2013 Medihelp s Necesse acute medicine formulary Dear Doctor/Pharmacist Medihelp is pleased to present the latest updated version of
More informationCommon Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More information500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device
3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationError! No text of specified style in document.
Inhaled corticosteroids and long-acting beta 2 -agonists for the treatment of chronic asthma in children under the age of 12 years: Systematic review and economic analysis Amended cost-off set comparisons
More informationInhaled Drug Delivery Systems
Inhaled Drug Delivery Systems eve r y b r e a t h f o r yo u Millions of people suffer every day from chronic respiratory diseases and these constitute a large part of a physician s practice. According
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationAsthma and the competitive swimmer
Asthma and the competitive swimmer Introduction: One in seven children and one in 25 adults in Great Britain have asthma and the number is growing. Thus every swim squad or club will have a number of asthmatics
More informationComparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature
Health Technology Assessment 2001; Vol. 5: No. 26 Review Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature D Brocklebank
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationChronic Illness Benefit medicine list (formulary) 2012
Chronic Illness Benefit medicine list (formulary) 2012 Discovery Health Chronic Illness Benefit 2012 Contents Page Explanation of terms 2 The Prescribed s medicine formulary (for all plan types) 3 Important
More informationChronic Obstructive Pulmonary disease 2006/05/25
Chronic Obstructive Pulmonary disease : 2006/05/25 Definition of COPD COPD is a disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2012 Discovery Health Chronic Illness Benefit 2012 Contents Page Explanation of terms 2 The Prescribed s medicine formulary (for all plan types) 3 Important
More informationAnglovaal Group Medical Scheme Chronic Illness Benefit medicine list
Anglovaal Group Medical Scheme Chronic Illness Benefit medicine list 2012 AVGMS Chronic Illness Benefit 2012 Contents Page Explanation of terms 3 The Prescribed Minimum Benefits medicine formulary 4 Important
More information10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
More informationMotohealth Custom Chronic Medicine Formulary
Motohealth Custom Chronic Medicine Formulary 2018 Chronic application forms must accompany all first-time applications. All applications MUST include valid ICD10 codes. Risk Equalisation Fund criteria
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationSUPPLEMENTARY MATERIAL. Supplementary methods. Optimum Patient Care questionnaires
1 SUPPLEMENTARY MATERIAL Supplementary methods Optimum Patient Care questionnaires Over 600 primary care practices in the United Kingdom contribute data to the Optimum Patient Care Research Database (OPCRD).
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More information(PLACE PATIENT LABEL HERE) Date: Time: Assessment nurse: Sign: STOP!
ASTHMA BEST CARE BUNDLE P A T H W A Y ADULT ASTHMA Date: Time: Assessment nurse: Sign: INCLUSION CRITERIA Known asthmatic Shortness of breath and / or wheeze EXCLUSION CRITERIA Chronic lung disease other
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationChronic Illness Benefit medicine list (formulary) 2017
Chronic Illness Benefit medicine list (formulary) 2017 Who we are The Malcor Medical Aid Scheme (referred to as the Scheme ), registration number 1547, is the medical scheme that you a member of. This
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationInhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2013 Anglovaal Chronic Illness Benefit 2013 Contents Page Explanation of terms 3 The Prescribed Minimum Benefits medicine formulary 4 Important information
More informationHe is still Short of Breath Is there any new puffer? Saidul Ansary
He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 SINGULAIR 4 mg chewable tablets Pack of 28 (CIP: 393 112-4) Pack of 50 (CIP: 393 118-2) SINGULAIR
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2013 Altron Medical Aid Chronic Illness Benefit 2013 Contents Page Explanation of terms 3 The Prescribed s medicine formulary (for all plan types) 4 Important
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2019 Chronic Illness Benefit 2019 Important information you need to know The Discovery Health Medical Scheme Rules set out the requirements for the Chronic
More informationModule Two: Managing Your Medicine and Symptoms. Copyright All rights reserved. Powered by Mediasphere.
Module Two: Managing Your Medicine and Symptoms Copyright 2017. All rights reserved. Powered by Mediasphere. Welcome Welcome to Module Two of Lung Foundation Australia s C.O.P.E program. C.O.P.E. stands
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationChronic Illness Benefit medicine list (formulary) 2017
Chronic Illness Benefit medicine list (formulary) 2017 Who we are LA Health Medical Scheme (referred to as 'the Scheme ), registration number 1145, is a non-profit organisation, registered with the Council
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2018 Chronic Illness Benefit 2018 Important information you need to know The Discovery Health Medical Scheme Rules set out the requirements for the Chronic
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2018 Chronic Illness Benefit 2018 Important information you need to know The Discovery Health Medical Scheme Rules set out the requirements for the Chronic
More informationTherapeutic brief 6. Inside. Key Points
Therapeutic brief 6 Inhaled respiratory medicines: optimising use in COPD The management of veterans with chronic obstructive pulmonary disease (COPD) often requires the use of several inhaled medicines
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationImproving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) 2015 Chronic Illness Benefit 2015 Contents Page Explanation of terms 3 The Prescribed Minimum Benefits medicine list 4 Important information you need to
More informationEnd Stage COPD Guidance Document
End Stage COPD Guidance Document Suggested Guidelines for the Determination of Hospice Eligibility A patient with severe chronic pulmonary disease that meets the following criteria may be eligible for
More informationChronic Illness Benefit medicine list (formulary)
Chronic Illness Benefit medicine list (formulary) - 2019 Who we are Remedi Medical Aid Scheme (referred to as 'the Scheme"), registration number 1430, is a non-profit organisation, registered with the
More informationDelivering Aerosol Medication in ICU
Delivering Aerosol Medication in ICU 18th Aug 2017 Lau Chee Lan Pharmacist HCTM PPUKM ASMIC 2017 Aerosol Therapy Part of the treatment for a variety of respiratory disease * asthma and chronic obstructive
More informationAsthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
More informationChronic Illness Benefit medicine list (formulary) 2018
Chronic Illness Benefit medicine list (formulary) 2018 Who we are Glencore Medical Scheme (referred to as 'the Scheme"), registration number 1253, is a non-profit organisation, registered with the Council
More informationMedicines Management of Asthma
Wandsworth Borough Team Medicines Management of Guidelines for Primary Care September 2011 Version 1 Guideline Authors: Shaneez Dhanji (Wandsworth borough) Reena Rabheru-Dodhy (Sutton & Merton borough)
More informationChronic Illness Benefit 2018
Chronic Illness Benefit 2018 Who we are TFG Medical Aid Scheme (referred to as 'the Scheme"), registration number 1578, is a non-profit organisation, registered with the Council for Medical Schemes. Discovery
More information